Mp57-20 Antidepressant Medication Use Among Commercially Insured Men With Depression Undergoing Inflatable Prosthesis Implantation

You have accessJournal of UrologyHealth Services Research: Value of Care: Cost and Outcomes II (MP57)1 May 2024MP57-20 ANTIDEPRESSANT MEDICATION USE AMONG COMMERCIALLY INSURED MEN WITH DEPRESSION UNDERGOING INFLATABLE PROSTHESIS IMPLANTATION Roei Golan, Young Shin, Alysha M. McGovern, Rutugandha Paranjpe, Sirikan Rojanasarot, Taylor Kohn, Francis Petrella, Sirpi Nackeeran, and Ranjith Ramasamy Roei GolanRoei Golan , Young ShinYoung Shin , Alysha M. McGovernAlysha M. McGovern , Rutugandha ParanjpeRutugandha Paranjpe , Sirikan RojanasarotSirikan Rojanasarot , Taylor KohnTaylor Kohn , Francis PetrellaFrancis Petrella , Sirpi NackeeranSirpi Nackeeran , and Ranjith RamasamyRanjith Ramasamy View All Author Informationhttps://doi.org/10.1097/01.JU.0001009420.83948.eb.20AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Depression often occurs alongside sexual dysfunction in men and can greatly reduce quality of life. Previous research shows inflatable penile prosthesis (IPP) implantation may improve depressive symptoms for these patients, suggesting benefits beyond erectile restoration. However, there is limited data on how IPP affects use of antidepressant medications for depression. This study aimed to investigate the impact of IPP placement on antidepressant prescription patterns in commercially insured American men diagnosed with depression. METHODS: A retrospective claims database analysis was conducted using the Merative™ MarketScan® commercial claims database to identify men aged 18+ with a depression diagnosis who underwent IPP implantation (Current Procedural Terminology CPT® code 54405) between 01/01/2007 and 12/31/2021 post-depression diagnosis. Included patients were required to have at least 1 year of continuous enrollment pre-IPP and post-IPP and to have received an antidepressant prescription prior to their IPP date. Antidepressant utilization was assessed based on proportion days covered (PDC) (a measure of consistent use of a medication), number of prescriptions and refills, and discontinuation (defined as a gap of ≥90 days between refills) pre- and post-IPP. A paired t-test was performed to assess the differences before and after IPP implantation. RESULTS: A total of 678 men diagnosed with depression who underwent IPP were identified with an average age of 55.8±6.4 and Charlson Comorbidity Score of 1.6±1.6 pre-IPP. Of these patients, 104 (15%) had no antidepressant prescriptions in the post-IPP follow-up period, representing a complete stop of treatment. For the 574 men with antidepressant prescriptions following IPP (Table 1), the number of antidepressant prescriptions and refills decreased significantly from post-implantation. Patients were also significantly more likely to discontinue their antidepressant treatment and had lower PDC post-IPP versus pre-IPP. CONCLUSIONS: The study found a significant decline in antidepressant utilization post-IPP implantation, emphasizing IPP's potential role in not only addressing erectile function but also influencing mental health outcomes. Further research may evaluate the causative factors and implications of these findings on patient care and treatment approaches. Source of Funding: This study was supported by Boston Scientific. RR is a practicing urologist at University of Miami and discloses financial interest with Boston Scientific (consultant, grant recipient). RP and SR are employees of Boston Scientific. YS is a graduate student at the University of Cincinnati and is not a Boston Scientific employee; however, she is working on a Global Health Economics and Market Access project with Boston Scientific.Supported by NIDDK grants R01 DK130991, UE5 DK137308, and Clinician Scientist Development Grant from American Cancer Society to RR © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e946 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Roei Golan More articles by this author Young Shin More articles by this author Alysha M. McGovern More articles by this author Rutugandha Paranjpe More articles by this author Sirikan Rojanasarot More articles by this author Taylor Kohn More articles by this author Francis Petrella More articles by this author Sirpi Nackeeran More articles by this author Ranjith Ramasamy More articles by this author Expand All Advertisement PDF downloadLoading ...